Delcath Systems, Inc.

DCTH

$16.69

+0.66%

2026-09-03 09:30:01 EDT+$0.11

Healthcare

Medical - Devices

NASDAQ

Active Trading

Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary ...

Price Action of DCTH

$16.69

+0.66%+$0.11

High—

Low—

52W High-4.2%

Rel. vol—

Interval

Range6.5h

Volume—SMA5SMA10

—

Delcath Systems, Inc. is a specialty pharmaceutical and medical device company dedicated to advancing liver-targeted therapies for patients with liver-dominant cancers. The company's lead product, HEPZATO KIT (melphalan for Injection/Hepatic Delivery System), is FDA-approved for adult patients with metastatic uveal melanoma, a rare and aggressive form of eye cancer that ...Delcath Systems, Inc. is a specialty pharmaceutical and medical device company dedicated to advancing liver-targeted therapies for patients with liver-dominant cancers. The company's lead product, HEPZATO KIT (melphalan for Injection/Hepatic Delivery System), is FDA-approved for adult patients with metastatic uveal melanoma, a rare and aggressive form of eye cancer that spreads to the liver. The HEPZATO KIT is a unique hepatic delivery system designed to administer high-dose chemotherapy directly to the liver while minimizing systemic exposure and side effects. In Europe, the same technology is marketed as CHEMOSAT, which is used to treat a variety of liver cancers. Delcath's clinical development includes the FOCUS trial, which assesses objective response rates in patients with metastatic uveal melanoma. The company was founded in 1988 and is headquartered in Queensbury, New York. It employs around 156 people and operates in the United States and Europe. Financially, Delcath has shown growing revenue and improved margins, with a gross profit margin of 87.1% and a positive net profit margin of 0.6% as of the latest TTM. The company has a market cap of about $521 million and is listed on NASDAQ. Key executives include CEO Gerard J. Michel and board member Dr. Bridget Martell. Delcath is committed to expanding its commercial footprint and pipeline, with a focus on improving survival and quality of life for cancer patients.ExpandCollapse

Founded

1988

Employees

156

CEO

Gerard J. Michel

Full Name

Delcath Systems, Inc.

Sector

Healthcare

Industry

Medical - Devices

ROE

0.46%

Market Cap

$0.58B

Current Ratio

9.83

WACC

6.98%

ROIC

0.44%

Contact Information

https://www.delcath.com

212 489 2100

566 Queensbury Avenue, Queensbury, NY 12804

Key Metrics of DCTH

Snapshot

Latest / TTM · 6 periods

Market Cap

$576.17M

ROCE

-1.5%

EV / EBITDA

309.06x

-2.1% YoY

FCF Yield

3.1%

-2.7% YoY

Cash Conversion Cycle

288.5d

Current Ratio

9.83

Quick take

TTM —

Positive CCC

Financial Highlights of DCTH

Profitability trend

Latest / TTM · 6 periods

Gross Margin

87.1%

Net Margin

0.6%

P/E Ratio

1498.18x

n/a

Debt / Equity

0.02

n/a

Current Ratio

9.83

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of DCTH

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.09 · Revenue $26.00M · 2 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.14 · Revenue $26.31M · 2 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-0.18 · Revenue $106.44M · 3 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-0.05 · Revenue $32.27M · 1 analysts

Recent history

Aug 6, 2026
Q2 FY2026 · Results reported
EPS $0.07 · Revenue $29.13M
View filing
May 7, 2026
Q1 FY2026 · Results reported
EPS $-0.03 · Revenue $24.99M
View filing
Feb 26, 2026
FY2025 · Annual results
EPS $0.07 · Revenue $85.23M
View filing
Nov 4, 2025
Q3 FY2025 · Results reported
EPS $0.02 · Revenue $20.56M
View filing
Aug 6, 2025
Q2 FY2025 · Results reported
EPS $0.07 · Revenue $24.16M
View filing
May 8, 2025
Q1 FY2025 · Results reported
EPS $0.03 · Revenue $19.78M
View filing

Financial Statements of DCTH

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$85.2M	+129.1%	+16.6%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$2.7M	+110.2%	+349.3%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+86.2%	+3.3%	+5.5%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	+0.8%	+102.3%	+225.5%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	+3.2%	+104.5%	+313.9%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$21.0M	+209.0%	+1715.0%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	+24.6%	+147.6%	+1457.1%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	0.8%	-44.3%	+152.6%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	10.92x	-9.1%	-12.6%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$123.6M	+61.4%	+9.8%

Actual vs Estimate

A Dec 31Q Sep 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	0.07 vs 0.05	+40.8%	0.07 vs -0.09	+176.1%
Revenue Surprise	$85.2M vs $85.1M	+0.2%	$29.1M vs $26.0M	+12.1%

Insider Transactions of DCTH

Acquisitions (A)

Since Feb 17, 2026

Disposals (D)

Since Feb 17, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
May 13, 2026	Sylvester John Richard	director	Stock Option (right to buy)	A	22,500	$11.61
May 13, 2026	Martell Bridget A	director	Stock Option (right to buy)	A	22,500	$11.61
May 13, 2026	CZEREPAK ELIZABETH	director	Stock Option (right to buy)	A	22,500	$11.61
May 13, 2026	SALAMON STEVEN A J	director	Stock Option (right to buy)	A	22,500	$11.61
May 13, 2026	Aharon Gil	director	Stock Option (right to buy)	A	22,500	$11.61

Earnings Call Transcript of DCTH

1 transcript segments

Q1 2026

Unknown Speaker

Operator: Good morning, ladies and gentlemen, and welcome to the Delcath Systems First Quarter 2026 Earnings Conference Call. [Operator Instructions] This call is being recorded on Thursday, May 7, 2026. I would now like to turn the conference over to David Hoffman. Please go ahead. David Hoffman: Thank you, and welcome to Delcath Systems First Quarter 2026 Earnings Call. With me on the call are Gerard Michel, Chief Executive Officer; Sandra Pennell, Chief Financial Officer; Kevin Muir, Chief Commercial Officer; Vojislav Vukovic, Chief Medical Officer; and Martha Rook, Chief Operating Officer. This statement is made pursuant to the safe harbor for forward-looking statements described in the Private Securities Litigation Reform Act of 1995. All statements made on this call, with the exception of historical facts, may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the company believes that expectations and assumptions reflected in these forward-looking statements are reasonable, it makes no assurance that such expectations will prove to have been correct. Actual results may differ in a material manner from those expressed or implied in forward-looking statements due to various risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those expressed or implied in the forward-looking statements, please see risk factors detailed in the company's annual report on Form 10-K, those contained in filed quarterly reports on Form 10-Q as well as in other reports that the company files from time to time with the Securities and Exchange Commission. Any forward-looking statements included in this call are made only as of the date of this call. We do not undertake any obligation to update or supplement any forward-looking statements to reflect subsequent knowledge, events or circumstances. Our press release with our first quarter 2026 results is available on our website under the Investors section and includes additional details about our financial results. Our website also has our latest SEC filings, which we encourage you to review. A recording of today's call will be available on our website. Now I would like to turn the call over to Gerard. Gerard, please proceed. Gerard Michel: Thank you, David, and welcome, everyone. We've had a very successful first quarter marked by 4-centre activations and record new patient starts in the first quarter, both of which are core growth drivers for the business. In addition, we continue to advance numerous commercial and medical initiatives to ensure the long-term growth of HEPZATO with a strong focus on a third critical growth driver, building referral networks to quickly connect eligible patients with treating centers. To support center activations, increased utilization at existing centers and expanded referral patterns, we have …

Leadership Team of DCTH

8 executives

Name	Title	Compensation	Gender	Year Born	Status
Gerard J. Michel	Chief Executive Officer & Director	USD 990,707	Male	1963	Active
Vojislav Vukovic	Chief Medical Officer	USD 672,000	—	1967	Active
Martha S. Rook	Chief Operating Officer	USD 640,833	—	1971	Active
Johnny John	Senior Vice President of Clinical Operations & Medical Affairs	USD 472,163	—	1965	Active
Kevin Muir	Chief Commercial Officer	USD 394,402	Male	—	Active
Michael Brunner	Senior Vice President of Interventional Oncology	—	—	—	Active
David Hoffman	General Counsel, Corporate Secretary & Chief Compliance Officer	—	Male	1970	Active
Sandra Pennell	Chief Financial Officer	—	Female	1979	Active

Recent News of DCTH

Zacks Investment Research8/28/2026Neutral

What Makes Delcath Systems, Inc. (DCTH) a Strong Momentum Stock: Buy Now?

Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research8/28/2026Neutral

Recent Price Trend in Delcath Systems (DCTH) is Your Friend, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, Delcath Systems (DCTH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks Investment Research8/27/2026Neutral

Wall Street Analysts Believe Delcath Systems (DCTH) Could Rally 52.44%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 52.4% in Delcath Systems (DCTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research8/12/2026Neutral

Delcath Systems (DCTH) Is a Great Choice for 'Trend' Investors, Here's Why

Zacks Investment Research8/11/2026Neutral

Here's Why Delcath Systems, Inc. (DCTH) is a Great Momentum Stock to Buy

Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Historical Employee Count of DCTH

Current

156

Change

+62.50%

Minimum

Maximum

156

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	156	10-K	Feb 26, 2026	View
Dec 31, 2024	96	10-K	Mar 6, 2025	View
Dec 31, 2023	76	10-K	Mar 26, 2024	View
Dec 31, 2022	52	10-K	Mar 27, 2023	View
Dec 31, 2021	55	10-K	Mar 31, 2022	View

Related stocksMedical - Devices

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Delcath Systems, Inc.